VPC
ARQT icon

Vestal Point Capital’s Arcutis Biotherapeutics ARQT Stock Holding History

Vestal Point Capital’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-200,000
Closed -$3.77M – 78
2025
Q3 		$3.77M Buy
200,000
+105,000
+111% +$1.66M 0.17% 70
2025
Q2 		$1.33M Buy
+95,000
New +$1.33M 0.07% 68
2024
Q1 		– Sell
-2,700,000
Closed -$8.72M – 59
2023
Q4 		$8.72M Buy
+2,700,000
New +$7.34M 0.92% 28

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vestal Point Capital's ARQT Position: Q4 2025 in Review

Vestal Point Capital sold out of Arcutis Biotherapeutics (ARQT) in Q4 2025, closing a stake of 200,000 shares — an estimated $3.77M sold.

Vestal Point Capital first reported a position in ARQT in Q4 2023 and held it in 3 quarters. The position peaked at $8.72M in Q4 2023. 283 funds tracked by Wall St. Rank hold ARQT as of Q4 2025.

  • Vestal Point Capital reported no remaining Arcutis Biotherapeutics position as of Q4 2025 after selling out during the quarter.
  • Vestal Point Capital sold 200,000 Arcutis Biotherapeutics shares in Q4 2025, an estimated $3.77M.
  • Vestal Point Capital first reported a position in Arcutis Biotherapeutics in Q4 2023 and held it in 3 quarters.
  • Vestal Point Capital's Arcutis Biotherapeutics position peaked at $8.72M in Q4 2023.
  • 283 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2025.

Based on Vestal Point Capital's 13F filing for Q4 2025, filed 17 Feb 2026.